Crinetics Pharmaceuticals
Develops oral GPCR medicines for endocrine diseases and endocrine-related tumors.
Something off on this page? Send us feedback.
Profile
Sells PALSONIFY, a once-daily oral treatment for acromegaly, while developing paltusotine for carcinoid syndrome and atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. Product revenue comes from PALSONIFY, and most other programs remain subject to clinical and regulatory approval.
Develops and commercializes oral small-molecule medicines for endocrine diseases and endocrine-related tumors, using in-house expertise in tailoring compounds to G protein-coupled receptors. PALSONIFY (paltusotine), its first marketed product, is a once-daily oral treatment for adults with acromegaly and is approved in the U.S. and European Union. Paltusotine is also being studied for carcinoid syndrome.
Atumelnant, an oral ACTH receptor antagonist, is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. CRN09682 applies a nonpeptide drug-conjugate platform to somatostatin-receptor-expressing tumors, while discovery programs pursue other endocrine and metabolic targets.
Product revenue comes from PALSONIFY, manufacturing is outsourced, and most pipeline programs still require clinical and regulatory approval. A definitive agreement calls for Vertex Pharmaceuticals to acquire the business, subject to shareholder, regulatory, and other closing conditions.
Company facts
Key statistics
Year to date +81.6% · Average volume (30d) 2.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 28, 2026 | UBS | Downgrade | Buy | Neutral | ||
| Jul 27, 2026 | UBS | Downgrade | Buy | Neutral | $55 | $85 |
| Jul 8, 2026 | Stifel Nicolaus | Target | $83 | $85 | ||
| Jul 8, 2026 | TD Cowen | Downgrade | Buy | Hold | ||
| Jul 8, 2026 | Evercore ISI Group | Downgrade | Outperform | In Line |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$1.18 | −$1.14 | +3.4% | $14.8M | $25.1M | +69.2% | +0.17% |
| Aug 3, 2026Q2 FY26 | −$1.18 | −$1.14 | +3.4% | $14.8M | $25.1M | +69.2% | +0.12% |
| May 7, 2026Q1 FY26 | −$1.22 | −$1.23 | −0.8% | $8.5M | $10.7M | +26.1% | −13.82% |
| Feb 26, 2026Q4 FY25 | −$1.37 | −$1.29 | +5.8% | $4.5M | $6.2M | +37.2% | −6.04% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $361.0K | $1.0M | $143.0K | $6.2M | $10.7M | $25.1M | |
| Gross profit | $361.0K | $1.0M | $143.0K | $6.2M | $10.5M | $25.0M | |
| Operating income | −$111.4M | −$129.1M | −$142.6M | −$133.7M | −$140.4M | −$132.5M | |
| Net income | −$96.8M | −$115.6M | −$130.1M | −$122.8M | −$127.8M | −$120.9M | |
| Diluted EPS | −$1.04 | −$1.23 | −$1.38 | −$1.30 | −$1.23 | −$1.14 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 98.1% | 99.4% | |
| Operating margin | -30,860.1% | -12,523.0% | -99,710.5% | -2,169.6% | -1,307.8% | -527.3% |
Fiscal years (4-quarter sums)FY21 $1.1M · FY22 $4.7M · FY23 $4.0M · FY24 $1.0M · FY25 $7.7M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.21B · Total debt $47.2M · Total assets $1.32B · Shareholders' equity $1.19B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 105.97M · Float 99.41M · 93.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.84M | 14.95% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 9.76M | 9.21% | 13F | Aug 7, 2026 |
| Farallon Capital Management LLC | 8.99M | 8.48% | 13F | Aug 14, 2026 |
| Wellington Management Group LLP | 7.13M | 6.73% | 13F | Aug 14, 2026 |
| Driehaus Capital Management LLC | 6.46M | 6.10% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 2, 2026 | Coelho Rogerio Vivaldi | director | −3,000 | $40.00 |
| Jun 17, 2026 | Stephanie Okey | director | −6,900 | $35.67 |
| Apr 8, 2026 | Jeff E. Knight | officer: Chief Dev. & Operating Officer | −85,163 | $40.10 |
| Mar 16, 2026 | Richard Scott Struthers | director, officer: President & CEO | −21,981 | $37.37 |
| Mar 16, 2026 | Stephen F. Betz | officer: Chief Scientific Officer | −10,612 | $37.37 |
Peers
- Novartis (ADR)
Dominant SSA and radioligand incumbent in acromegaly and NET therapy
- Neurocrine Biosciences
First FDA-approved CAH therapy (Crenessity) generating $301M in its launch year.
- Corcept Therapeutics
Cushing's syndrome franchise with Korlym ($761M) and pipeline relacorilant
- Pfizer
Somavert, the only approved GH receptor antagonist, in second-line acromegaly
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals | $84.97 | +0.13% | $8.99B | — | — | 213.3 | +2,336.3% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Neurocrine Biosciences | $154.94 | +0.57% | $15.49B | 22.6 | 16.9 | 4.6 | +39.5% |
| Corcept Therapeutics | $115.08 | +1.06% | $12.31B | 271.1 | 28.5 | 14.8 | +31.7% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Median | 30.1 | 16.6 | 4.9 | +17.2% |